December 15, 2004 (Press Release) --
Aethlon Medical Discusses Potential to Treat Patients Co-Infected With Both HIV/AIDS and Hepatitis C
Aethlon Medical, Inc. (OTCBB: AEMD) www.aethlonmedical.com announced today that its Hemopurifier(TM) treatment technology has demonstrated multi-pathogen clearance capabilities that could lead to a simultaneous treatment for persons infected with both HIV and the Hepatitis C virus (HCV). The Hemopurifier is a medical device that converges the use of hollow-fiber dialysis technology with affinity chromatography to separate and selectively capture viruses and toxins from the blood. Recent enhancements to the Hemopurifier include the immobilization of a single affinity agent that is able to attach to the surface of both HIV and HCV.
Disclaimer: www.investorideas.com/about/disclaimer
Full News: www.investorideas.com/Companies/ViewDocument.asp?ID=2432
Aethlon Medical, Inc. (OTCBB: AEMD) www.aethlonmedical.com announced today that its Hemopurifier(TM) treatment technology has demonstrated multi-pathogen clearance capabilities that could lead to a simultaneous treatment for persons infected with both HIV and the Hepatitis C virus (HCV). The Hemopurifier is a medical device that converges the use of hollow-fiber dialysis technology with affinity chromatography to separate and selectively capture viruses and toxins from the blood. Recent enhancements to the Hemopurifier include the immobilization of a single affinity agent that is able to attach to the surface of both HIV and HCV.
Disclaimer: www.investorideas.com/about/disclaimer
Full News: www.investorideas.com/Companies/ViewDocument.asp?ID=2432

Aethlon Medical Discusses Potential to Treat Patients Co-Infected With Both HIV/AIDS and Hepatitis C
Email
Print
SPAM




